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Abstract
Research increasingly suggests that subjective cognitive decline (SCD) in older adults, in the 
absence of objective cognitive dysfunction or depression, may be a harbinger of non-normative 
cognitive decline and eventual progression to dementia. Little is known, however, about the key 
features of self-report measures currently used to assess SCD. The Subjective Cognitive Decline 
Initiative (SCD-I) Working Group is an international consortium established to develop a 
conceptual framework and research criteria for SCD (Jessen et al., 2014, Alzheimers Dement 10, 
844–852). In the current study we systematically compared cognitive self-report items used by 19 
SCD-I Working Group studies, representing 8 countries and 5 languages. We identified 34 self-
report measures comprising 640 cognitive self-report items. There was little overlap among 
measures—approximately 75% of measures were used by only one study. Wide variation existed 
in response options and item content. Items pertaining to the memory domain predominated, 
accounting for about 60% of items surveyed, followed by executive function and attention, with 
16% and 11% of the items, respectively. Items relating to memory for the names of people and the 
placement of common objects were represented on the greatest percentage of measures (56% 
each). Working group members reported that instrument selection decisions were often based on 
practical considerations beyond the study of SCD specifically, such as availability and brevity of 
measures. Results document the heterogeneity of approaches across studies to the emerging 
construct of SCD. We offer preliminary recommendations for instrument selection and future 
research directions including identifying items and measure formats associated with important 
clinical outcomes.
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INTRODUCTION
Subjective cognitive decline (SCD) in older adults is increasingly recognized as a potential 
indicator of non-normative cognitive decline and eventual progression to dementia [1–5]. 
Moreover, there is emerging evidence of associations of SCD with Alzheimer’s disease 
(AD) biomarkers and neuroimaging markers [6–16], such as gray matter volume loss [6–8], 
cerebral hypometabolism [10], and amyloid deposition [12–14], in the absence of objective 
cognitive dysfunction or depression. Given research supporting SCD as a risk factor for AD 
in some individuals, the National Institute on Aging–Alzheimer’s Association preclinical 
AD working group has included SCD as a feature, highlighting its importance in disease 
detection and prevention [17]. In addition to preclinical AD, SCD is relevant to other 
conditions affecting older adults, for example: depression and anxiety [18–19], physical 
health problems and common chronic diseases [18, 20], and non-AD dementias [1, 21].
By definition, SCD is contingent on self-report of cognition, and this assessment approach is 
associated with certain practical advantages such as brevity, ease of administration, and low 
cost [22]. However, the field currently lacks a single accepted approach to the assessment of 
SCD, including the fundamental nature of the questions (present status versus decline), 
cognitive domains of greatest interest, and optimal items for each domain [22, 23]. Also, 
since the prevalence of cognitive complaints in the general adult population is relatively 
high [24] and can be affected by factors such as mood and personality [25], it becomes 
difficult to ascertain which complaints indicate underlying AD versus other 
neurodegenerative pathologies or psychological conditions. This underscores the need for a 
high degree of rigor in deriving self-report items with concurrent validity for the construct of 
SCD and predictive validity for future cognitive and clinical outcomes. The definition of the 
external validators for SCD is itself the subject of discussion [22, 23].
In contrast to extensive efforts to refine and standardize AD biomarkers [26–28] and criteria 
for conditions such as mild cognitive impairment (MCI) [29–33], research on the 
standardization and quantification of SCD is relatively limited. Many approaches are used to 
define and quantify SCD and related constructs, such as cognitive complaints, memory 
complaints, subjective memory impairment, and subjective cognitive impairment, with no 
agreed-upon standards [22, 23]. The variability in definition and large number of operational 
procedures for assessing SCD makes it difficult to compare findings and refine the construct 
for use in clinical and research settings.
A review of both the SCD and broader cognitive aging literature suggests heterogeneity in 
important aspects of cognitive self-report measures including mode of administration [34–
41], number of items [42–53], and response option types [38, 54–59]. Other dimensions on 
which self-report measures vary are item content and complexity including whether items 
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relate to memory exclusively [57, 60–62] or include additional cognitive domains [50, 63, 
64] or non-cognitive items [51, 55, 65], whether items tap current cognitive ability or 
disability/impairment [65–67] versus intraindividual change [57, 68], and whether items 
inquire about general versus specific aspects of cognition. In terms of the origin of 
instruments, while some studies use complete published questionnaires [54–60, 65], others 
use groups of items from existing measures [69–71] or develop new items for a specific 
study [12, 72–77]. Finally, while selecting appropriate measures stands among the most 
critical decisions made in clinical research contexts, the SCD literature in many cases does 
not thoroughly discuss selection decisions.
An international consortium known as the Subjective Cognitive Decline Initiative (SCD-I) 
Working Group recently was established to develop common terminology and basic criteria 
for SCD to enable joint research efforts across studies and settings [23]. The current study 
describes the characteristics of self-report measures employed by studies represented by 
SCD-I investigators. Specifically, we focus on key structural and content validity issues and 
investigate content overlap among the questionnaire items as well as questionnaire selection 
decisions. Our goals are to identify areas of variability and consistency, raise issues related 
to the adequacy of assessment approaches, and ultimately develop improved tools for 
diverse research and clinical settings.
MATERIALS AND METHODS
The SCD-I
The SCD-I was launched in October 2012 and formed a working group that included AD 
researchers with a specific interest in SCD. Members were identified by a systematic 
literature search in addition to targeted inclusion of leading researchers in the field of 
preclinical AD assessment. The working group’s first project established a conceptual 
framework and research criteria for SCD [23]. Members of the SCD-I were subsequently 
invited to participate in the current item analysis project.
Questionnaire characteristics and coding procedures
Based on our review of the SCD literature, considerations of relevance to the field, and 
feasibility, we investigate the following ten issues through descriptive and content analysis 
of SCD-I Working Group measures: (1) number of self-report measures used by 
participating working group studies; (2) origin of instruments and mode of administration; 
(3) format and range of response options; (4) timeframe referenced by the items; (5) 
prevalence of items related to specific cognitive domains; (6) prevalence of items tapping 
cognitive ability/disability-impairment (and referents of frequency, severity, and impact) 
versus change or decline (and referents of temporal and atemporal); (7) item specificity and 
complexity; (8) overlap in measures used by working groups; (9) most commonly occurring 
items; and (10) considerations driving measure selection and the grouping of questionnaires 
within a given study. Coding of cognitive self-report items occurred prior to data analysis 
for research issues 1, 5, 6, 7, 9, and 10. For all coding procedures, working group member 
LAR carried out the initial coding. Two additional expert raters (working group members 
CMS and SAMS) subsequently identified items that they considered to be miscoded. Items 
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in dispute were then reviewed and discussed until consensus was reached, occasionally after 
discussing disputed items with working group member PKC.
Selection of cognitive items
SCD-I Working Group members sent electronic copies of their subjective self-report 
measures to author LAR. For studies conducted in a language other than English, working 
group members sent a translated version of their measures. The raters then reviewed all 
measures to determine whether they merited inclusion in the current study by virtue of 
containing items that assess the self-perception of memory and other cognitive abilities. 
Notably, while the raters recognized that mood, anxiety, health complaints, and other 
variables are relevant to SCD and often included in cognitive self-report measures, they are 
not the focus of the current study.
Categorization by cognitive domain
The raters next classified items by cognitive domain. They first developed a list of cognitive 
domain categories under which to subsume all items. The list was revised following 
feedback from additional working group members and included the following categories: (1) 
memory (short-term/long-term/episodic/semantic/prospective memory and learning new 
information); (2) attention/working memory/processing speed (also includes basic attention, 
sustained attention, focused attention, concentration, divided attention, and alertness); (3) 
language (expressive and receptive language, word finding, reading, and spelling); (4) 
executive function (organizing, planning, switching, initiating, multi-tasking, reasoning, 
judgment, problem solving, decision-making, handling emergencies, impulsivity and self-
regulation, clarity of mind, motor programming, handling money, and self-awareness of 
problems); (5) basic calculation and arithmetic tasks; (6) orientation to person, time, place, 
or situation; (7) general cognitive ability (memory and other thinking abilities grouped 
together in a single item); and (8) visuospatial skills (visuoperception, route finding, and 
directional orientation). The raters assigned each item to a single category using the widely-
recognized neuropsychological framework suggested by Lezak and colleagues [78]. Though 
many items arguably could be categorized into more than one cognitive domain, the raters 
assigned a primary category for each item.
Categorization by ability/disability and change
The raters considered each cognitive item (both stem and response options) to determine 
whether the item inquired about a participant’s ability to perform a given cognitive task or 
whether the item inquired about change (improvement or decline). For items that assess 
ability versus disability/impairment, items could portray the intensity or severity of 
problems, their frequency, or impact on everyday life. The raters therefore coded for 
referents of severity (degree of seriousness), frequency (rate of occurrence), and impact 
(effect on real-world outcomes). For items that assess change, items could portray temporal 
change (relative to a general or specific timeframe) or atemporal change (relative to peers, a 
previous state, or rate of change). The raters therefore coded for both temporal and 
atemporal referents.
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Categorization by item specificity and complexity
To address issues of item specificity and complexity, the raters coded memory items 
according to generality versus specificity and whether they were double-barreled (i.e., 
involved multiple sub-questions within the one item). A general memory item was defined 
as a cognitive self-report item that inquires about memory functioning without specifying a 
particular memory activity, problem, or task. The raters did not extend the coding of general 
versus specific items to cognitive domains other than memory because of the complexity of 
establishing coding criteria for non-memory domains. A double-barreled cognitive item was 
defined as an item that asks respondents to rate or respond to two or more different issues 
while allowing for only one response.
Most commonly occurring items
After close review of all items across the 34 questionnaires, the raters identified items with 
overlapping content (e.g., memory for recent events, memory for names, losing one’s train 
of thought) despite nonidentical item wording (as there were no items with verbatim 
wording for both item stems and response options). Subsequently, the raters generated a list 
of the 10 most common item themes.
Selection decisions
To understand the decision-making behind each research group’s choice of measures or 
development of new measures, the raters distributed a brief survey to working group 
members. The survey asked the following:
(1) for working groups utilizing existing cognitive self-report measures, respondents were 
asked to identify the “primary” self-report measure and state why the measure was initially 
selected for use, endorsing all responses that applied from among various options; (2) for 
working groups that developed their own cognitive self-report measures, respondents were 
asked to state why they chose to develop a new measure (free response); and (3) for working 
group studies that administered more than one cognitive self-report measure, respondents 
were asked to describe the rationale for including the specific number of measures in the 
study (free response).
RESULTS
Table 1 lists the names, institutional affiliations, and other key features of the 19 working 
group studies including country, research environment, approximate number of study 
participants, and number of SCD measures utilized. The United States houses the greatest 
number of working group studies (n = 7), followed by Germany (n = 3), Australia (n = 2), 
France (n = 2), and Spain (n = 2). Canada and the Netherlands house one study each, and the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) has multiple international locations 
including the United States, Canada, Australia, Germany, and the United Kingdom. There 
was substantial variability in terms of research environment, with representation of memory 
clinics (n = 4), volunteer samples (n = 3), community-based samples (n = 3), population-
based samples (n = 2), a general practice registry (n = 1), and mixed sampling approaches (n 
= 6).
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Below we present results related to the 10 instrument dimensions outlined in the Methods 
section.
(1) Number of self-report measures and items used
Table 2 presents the names and key structural and administrative features of the 34 self-
report measures used by the 19 studies. The number of measures used per study ranged from 
1 to 8 with a mean of 2.4 (SD = 2.1) and a mode of 1. While some measures included 
cognitive items exclusively, other measures primarily focused on mood or activities of daily 
living but included one or more cognitive items highly relevant to the current analysis. There 
were a total of 922 items across all measures. Of the 34 measures, 61.8% (n = 21) contained 
items that did not involve specific cognitive complaints. This included items related to the 
use of memory/other cognitive strategies, emotional and psychological functioning, 
reactions to cognitive changes, personality and interpersonal functioning, physical and 
motor functioning, vocational and social tasks, general health, fatigue or sleep behaviors, 
apraxia, basic activities of daily living, general health, general beliefs about memory and 
aging, and items that were not self-report. These non-SCD items were identified with <4% 
discrepancies between raters, eliminated for the purposes of the current study, and not 
considered further. All subsequent results relate to the subset of 640 cognitive items that tap 
the subjective perception of memory and other cognitive abilities, representing 69.4% of the 
total items across the 34 questionnaires. The number of cognitive items per questionnaire 
ranged from 1 to 56 with a mean of 18.8 (SD = 15.5). Table 2 shows the percentage of 
cognitive self-report items within each questionnaire.
(2) Origin of instruments and mode of administration
With respect to the origin of their instruments, working group studies utilized existing 
published questionnaires and instruments developed specifically for their research studies 
with equal frequency (15 each, accounting for 88% of all measures). The remaining 12% of 
measures (n = 4) comprised subsets of items from lengthier published measures. The vast 
majority of measures (82.4%, n = 28) were self-administered via paper questionnaire. The 
remaining measures were examiner-administered by telephone (8.8%, n = 3) or in person 
(8.8%, n = 3); in both cases, examiners read the questions aloud to participants and recorded 
responses.
(3) Format and range of response options
There was considerable variability in response options with 21 measures (61.8%) having a 
single type of response option and the remaining 13 having between 2 to 5 different option 
types within a single measure (see Table 2). Traditional Likert and rank-ordered/categorical 
item scales were the most common, appearing on 27 (79.4%) measures. Dichotomous 
(yes/no) response options were also common, with 8 (23.5%) measures employing this 
format. An additional 7 (20.6%) measures used response options with yes/no/don’t know or 
yes/no/prefer not to answer formats. Four measures (11.8%) used free response options, 
which were primarily for reporting the age of onset of cognitive symptoms.
Figure 1 presents information related to response options in terms of the scaling methods 
and item response content. Five- and 7-point scales were used most often, accounting for 
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30.5% (n = 195) and 20.3% (n = 130) of items, respectively. We categorized response 
options into 12 types. Scales from “always” to “never” (or similar) were used most often, 
comprising 26.6% (n = 170) of all items in the form of 7-point, 5-point, 4-point, and 3-point 
scales. Other commonly used response options were yes/no, yes/no/don’t know, and yes/no/
prefer not to answer (19.5%, n = 125); “better” to “worse” (or similar) in the form of 9-
point, 7-point, 5-point, and 4-point scales (15.6%, n = 100); and “strongly disagree” to 
“strongly agree” in the form of 5-point and 4-point scales (9.4%, n = 60). All content 
categories are represented in Fig. 1.
(4) Timeframe
As shown in Table 2, the most common response timeframe referred to by the cognitive 
items was the recent past with 47.1% (n = 16) of measures asking participants to reflect 
about current functioning or functioning over the past week, 2 weeks, or 6 months. An 
additional 5.9% (n = 2) of measures referenced the past year. Other measures required 
comparisons to 5 years ago (n = 3), 10 years ago (n = 3), and lengthier timeframes including 
“younger,” “ever before”, and “high school or college” (n = 3). The remaining measures (n 
= 7) referenced more than one timeframe within a single questionnaire.
(5) Prevalence of items related to specific cognitive domains
The raters categorized each item according to one of eight neuropsychological domains, 
with rater discrepancies arising in <4% of cases. As shown in Fig. 2, memory items 
represented the majority (58.6%, n = 375) of items, followed by executive function (15.8%, 
n = 101), attention/working memory/processing speed (10.8%, n = 69), and language (8.1%, 
n = 52). The remaining four domains of visuospatial skills, general cognitive ability, 
orientation, and basic calculation/arithmetic tasks together accounted for 6.7% of items (n = 
43).
(6) Prevalence of items tapping ability/disability-impairment versus change
We further investigated item content by categorizing items as ability/disability-impairment 
versus change; coding discrepancies between raters arose in <4% of cases. Of the 640 
cognitive items, 58.4% (n = 374) tapped ability/disability-impairment and 41.6% (n = 266) 
assessed intraindividual change or decline. Of the 374 items tapping ability/disability-
impairment, 49.5% (n = 185) assessed ability in terms of frequency, 44.7% (n = 167) 
assessed ability in terms of severity, and the remaining 5.9% (n = 22) of items assessed 
ability in terms of its impact on functioning. Of the 266 items assessing intraindividual 
change or decline, 97.7% (n = 260) assessed change in diachronic (or temporal) terms while 
6 items (2.3%) assessed change in synchronic (or atemporal) terms. Table 3 presents 
example items within these various content designations.
(7) Item specificity and complexity
We next considered item stem specificity, which refers to whether an item is general or 
specific, and complexity, which refers to whether items are double-barreled. As noted 
above, we limited our coding of general and specific items to memory items and did not 
extend this coding to other cognitive domains. There were discrepancies in <3% of cases for 
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specificity and <2% for complexity. The vast majority of the 375 memory items were 
specific (70.7%, n = 265) as opposed to general (29.3%, n = 110). In addition, 98 of the 640 
(15.3%) cognitive items were double-barreled. Tables 4 and 5 present examples of general 
and specific items and double-barreled items, respectively.
(8) Overlap in measures used by working groups
Table 6 shows the overlap in use of self-report measures by the working group studies. The 
34 measures were used 46 times by the 19 working group studies; each study incorporated 
from 1 to 8 measures. Of the 34 measures, 25 (73.5%) were used only in a single study, 7 
(20.6%) were used in 2 studies, the MAC-Q was used in 3 studies, and the ECog was used in 
4 studies. Note that scales called that MAC-Q were actually used in 4 studies, but one study 
used a different timeframe so the raters designated the versions as MAC-Qa and MAC-Qb 
(see Tables 2 and 6).
(9) Most commonly occurring items
We next coded the most commonly occurring items (i.e., items grouped together because 
they inquire about the same cognitive issue), with <4% discrepancies between raters. Table 
7 presents the items that appear most frequently across the 34 questionnaires and their item 
counts. Note that in some cases a particular item is administered more than once within a 
measure. Items related to memory change and memory for the names of people were most 
common, followed by general memory problems and remembering where the participant 
had put common objects. We also determined item commonality by identifying items that 
appear on the most measures. For this analysis we only counted each item once per 
questionnaire. As shown in Table 7, items relating to memory for the names of people and 
remembering where the individual had put common objects appeared on the greatest number 
of self-report measures, followed by general memory problems, word finding, and 
remembering appointments.
(10) Considerations driving questionnaire selection and the grouping of measures within a 
given study
For working groups that reported using an existing SCD measure as their “primary” 
cognitive self-report measure (n = 10), the most commonly endorsed reasons were the 
measure’s availability to the researchers, the measure’s brevity and convenience of 
administration, and the routine use of the measure in studies of cognitive impairment in 
aging (see Table 8). For working groups that reported developing their own cognitive self-
report measure (n = 9), reasons cited related to one of three general themes: (1) 
categorization of participants into SCD versus non-SCD groups; (2) addressing concerns 
specific to SCD individuals not captured by other measures; and (3) enabling the researchers 
to tap cognitive domains of interest. For working groups that reported using more than one 
self-report measure within a specific study (n = 7), reasons cited related to one of four 
general themes: (1) use of one measure to classify SCD and additional measure(s) to 
quantify specific aspects of cognitive functioning; (2) for complete coverage of domains of 
interest; (3) to permit more variability in the distribution of responses; and (4) to replicate 
what is used by other studies with similar participant demographics.
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DISCUSSION
Overview of findings
The current study is the first to provide a systematic descriptive summary of the cognitive 
self-report measures used in 19 international cognitive aging studies affiliated with the 
Subjective Cognitive Decline Initiative(SCD-I)Working Group. Participating studies were 
diverse with respect to research environment, number of participants, number of self-report 
measures utilized, and language in which measures were administered. Results indicated that 
participating studies adopted a wide range of methods to assess SCD—specifically, 34 
different self-report measures—the vast majority of which used only within a single study. 
Measures most commonly used across studies were the MAC-Q [57] and ECog [68], each 
used at four sites, though two different timeframes were used for the MAC-Q. Almost all 
self-report measures were self-administered in paper-and-pencil format. The cognitive 
domain most often targeted was memory, followed by executive function. Items related to 
memory for the names of people, remembering placement of common objects, and general 
memory problems occurred on the greatest percentage of measures. The vast majority of 
memory items tapped specific, rather than general, aspects of memory functioning.
Results highlight wide variation across studies ostensibly interested in the same construct 
and suggest that many factors may affect instrument choice beyond simple measurement of 
SCD. Most respondents indicated that measure selection decisions were based on 
accessibility and convenience of administration, as well as the frequency of use in the 
cognitive aging literature. Given that several sites reported very large sample sizes (i.e., 
>3,000 individuals), these decisions are understandable. Being mindful of participant and 
researcher burdens, this suggests that extensive batteries that fully characterize SCD may not 
be tractable for many sites to administer.
Our examination of currently used instruments demonstrated wide variation in the format, 
range, timeframe, and response options both within and across different measures. Items 
also varied as to whether they tapped ability/disability versus change or decline, with time 
referents for intraindividual change items ranging from the past 1, 2, 5, 10, or 20+ years to 
various other periods of life. Given that the subjective, first-person experience of SCD has 
been relatively understudied, such a broad swath of response options might increase the 
odds of successfully extracting the unique ways that various subgroups of individuals with 
SCD conceptualize their concerns.
There are limitations to quantifying an inherently subjective phenomenon such as a 
complaint. First, asking about complaints in such a large number of ways, largely a 
theoretical with regards to SCD, raises concern that group differences may emerge from 
type I error (i.e., statistical bias) incidence rather than actual distinction. In addition, large 
variability in reference periods has been shown to result in differing question interpretation 
and subsequent reporting by respondents [79, 80]. With shorter reference periods (e.g., over 
the past 6 months), respondents tend to report specific minor issues like forgetting names, 
whereas longer reference periods (e.g., over the past 5 years) tend to tap global, non-specific 
problems such as general age-related cognitive decline. In general, attentiveness to reference 
periods seems advisable [81]. Moreover, Likert (and related) formats used by many 
Rabin et al. Page 10
J Alzheimers Dis. Author manuscript; available in PMC 2015 October 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
measures assume an experience of SCD continuous with that of healthy older adults, 
distinguished only by degree of frequency or severity of complaint, which has not been 
established as factually evident. Indeed the perception of severity may well vary by 
demographic factors, such as education [82, 83] at the very least, so endorsement of the 
same items may mean different things to people of different experiential backgrounds. It is 
also noteworthy that a significant proportion of items (15%) were double-barreled, where 
participants could respond to either or both semantic referents, with no systematic way to 
address resultant ambiguity. This is particularly problematic when directly comparing self- 
and informant-responses to the same subjective report items, where double-barreled items 
make it impossible to determine which element(s) of an item stem a given respondent has 
addressed [84, 85].
A previous review of the SCD literature indicated that SCD has primarily been examined in 
longitudinal clinical research that follows individuals who decline to MCI and dementia 
over the course of the studies [86]. Retrospective examination of these cases determined that 
individuals often complained about declines in cognition many years before decline was 
detected on standardized clinical assessment—as long as 15 years before manifest cognitive 
impairment [86, 87]. Given that episodic memory is the cognitive domain most often 
impaired in MCI patients who subsequently progress to AD [30, 88], one would expect 
cognitive self-report measures to focus heavily on memory. This was borne out by our data, 
where well over half of all items and the most frequently occurring items pertained to 
memory. However, these memory items are not necessarily the best items to include in SCD 
assessments. In fact, several population-based studies suggest that a large percentage of 
older adults will endorse some complaint about memory [24, 82], and it is questionable 
whether the most commonly occurring memory items have the requisite sensitivity and 
specificity to reliably identify individuals progressing toward MCI and dementia. A report 
from the Nurses’ Health Study indicated that trouble following a group conversation or 
finding one’s way around familiar streets were more highly associated with the risk of 
cognitive impairment than memory complaints such as forgetting things from one moment 
to the next [89]. Finding one’s way in a familiar place might be classified as orientation or 
as spatial memory, a specific type of memory, and following a conversation might not be 
considered memory at all, but rather attention or executive function. Reisberg and 
colleagues specifically recommended use of the term cognitive rather than memory 
impairment precisely because the unique phenomenology of SCD is not fully understood 
and may not be limited to memory [86]. Thus, memory as typically conceived might not be 
the primary complaint of individuals with SCD due to preclinical AD, and items from other 
domains may prove to have better discriminant validity at this early stage of non-normative 
cognitive decline.
Considerations
The current study was intended to serve as a selective overview of the cognitive self-report 
measures used in studies performed by SCD-I Working Group members, whose primary 
focus is on preclinical AD. Thus, we were unable to include every extant self-report 
measure, and this may have biased results to some extent. However, we feel confident that 
we have captured many of the instruments used to assess cognitive complaints in large aging 
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cohort studies around the globe. In light of our findings, we provide several considerations 
for the measurement of SCD going forward:
First, the heterogeneity of measures used suggests the exercise of great caution in 
comparing findings across studies. This does not mean that every site investigating 
SCD should or could use exactly the same self-assessment battery. Research 
environment, for example, is an important consideration in selecting measures, as 
complaints likely mean something different in a population/volunteer sample as 
compared to a clinical sample. One might assume that individuals recruited from a 
clinic have specific concern or worry about their cognitive function, which is different 
from the report of complaints per se. While the literature tends to conflate complaints 
and concern, recent studies suggest that specific concern or worry about cognitive 
function has predictive value over and above complaints [21, 47].
Second, researchers might consider approaches from measurement science to inform 
proper selection of instruments to characterize SCD. Such approaches could be used to 
investigate the psychometric properties of existing measures, refine or shorten scales 
(by eliminating less informative items), or optimize measures for specific subgroups of 
the population of interest (e.g., a brief screen for SCD in a volunteer sample of highly 
educated older adults). Another application is computer adaptive testing, whereby 
participants are administered a set of self-report items tailored to their unique cognitive 
complaint profile estimated from previous item responses, resulting in use of the least 
number of items to estimate a person’s underlying subjective cognitive ability [90]. To 
our knowledge, computer algorithms to identify specific items to administer are not 
currently used. At a basic level it is necessary to investigate psychometric properties 
such as internal consistency, test-retest reliability, and content validity, as many of the 
instruments we reviewed were recently developed or not formally validated.
Third, more sophisticated and nuanced analytic approaches should be applied to the 
datasets on older adults available worldwide. At a minimum, this might include 
specificity and sensitivity analyses to derive items, for example, which discriminate 
SCD due to preclinical AD from healthy controls. Identifying items not only with 
sensitivity but also specificity for SCD is particularly salient in light of discussions 
about over-diagnosis and the potential to trigger a health crisis in the worried well if 
researchers over-screen for cognitive complaints [91].
Fourth, future research on SCD should include items related to mood, personality, and 
health. While the current study focused exclusively on cognitive self-report items, there 
is likely to be unique variance in perceived cognitive function explained by factors such 
as mood, personality, and health [69, 92–95]. Therefore, research on the predictive 
validity of self-report items should include non-cognitive measures to explain as much 
variance in the experience of SCD as possible. Additionally, we chose not to examine 
informant-report or clinician rating scales such as the Brief Cognitive Rating Scale, 
which incorporates various sources of information including self report of memory, 
objective observation of cognitive deficit on clinical interview, and assessment of 
functional ability [41]. These methods warrant investigation alongside self-report 
measures. Informant report, for example, may prove vital, not only in its own right, but 
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also with respect to how it converges or diverges with self-report at different points 
along the spectrum of pathologic cognitive decline [96].
Fifth, the meaning of complaints tends to vary as a function of demographic 
characteristics such as level of education and age. Two previous studies [82, 83], for 
example, found that cognitive complaints in highly educated participants were 
associated with increased risk of decline to AD. In fact, self-report measures may 
provide the optimal approach for measuring and monitoring high-functioning 
individuals in the earliest stages of neurodegenerative cognitive decline, since these 
individuals may perform at ceiling level on neuropsychological tests [93]. Age of 
participants also may impact the meaning of complaints, with research suggesting that 
memory concerns in the young-old associate with anxiety, depression, or personality 
variables, while memory complaints expressed by older individuals may reflect actual 
impairment or decline [82]. Cross-site collaboration may be fruitful to the extent that 
sites share a common setting and common participant demographics. However, any 
sensitivity and specificity analyses may need to be conducted within the context of local 
norms for response frequency.
Finally, as noted by Reisberg and colleagues [86], the first-person experience of SCD 
remains largely unknown. While one might assume that SCD varies from MCI and AD 
only by degree, it may manifest as a phenomenologically distinct entity. This is likely to 
be true at least to the extent that individuals with SCD are assumed to have preserved 
awareness of their difficulties when compared to individuals further along the spectrum 
of pathologic cognitive decline. Likewise, the first-person experience of SCD due to 
mood or health complaints may differ from the preclinical AD form of SCD. Aside 
from the psychometric strategies already discussed, another approach to characterizing 
SCD could involve gathering qualitative data from persons classified as SCD to reveal 
their first-person experience, including the frequency and types of complaints most 
salient to them. This approach would be sensitive to possible cultural differences in the 
expression of SCD and allow researchers to develop measures specific to their sample 
demographic characteristics.
Conclusions and recommendations
SCD is rapidly becoming a topic of major interest in cognitive aging and dementia. The 
current study is the first of its kind, involving an in-depth review of self-report measures 
currently employed by 19 international sites focused on the study of SCD. Overall, our 
findings serve as a call for international collaboration to promote harmonization and pooling 
of cognitive self-report data and greater consistency in the measurement of SCD. The 
majority of instruments we reviewed were developed within the past 10 years, in some cases 
within the context of a specific research study, and have limited psychometric evidence. 
However, validation is an ongoing process, and psychometric data are hopefully 
forthcoming. With these caveats in mind, we offer the following recommendations:
A. Select measures with appropriate demographic characterization:
• Ensure that your target population corresponds to the population for which 
the questionnaire was developed, understanding that response patterns may 
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vary as a function of demography (e.g., general population versus clinic-
based, young-old versus old-old participants). A good selection criterion is 
involvement of the target population in the questionnaire development 
process.
B. Select measures with adequate content coverage for the target population:
• Ensure that item stems are simple and easy to understand. Questionnaires 
should not contain double-barreled items, which are known to confuse 
respondents and undermine the accuracy of responses [84, 97].
• Combining multiple constructs within a single measure (e.g., items related to 
cognition in addition to aspects of mood, personality, or health status) may 
pose problems for calculating and interpreting scores and is generally not 
recommended.
• Inquire about cognitive issues that older adults encounter frequently in their 
daily lives. For example, while older adults routinely face the task of 
recalling a loved one’s name, some have never attempted to handle financial 
affairs and may rely on ideas about related skills they do possess, such as 
basic mathematics [117]. An optimal approach may involve tailoring 
questions to individuals based on knowledge about their particular 
experiences or medical history [117].
• Sample cognitive domains beyond episodic memory because items that tap 
into other aspects of memory, or other domains, might be more 
pathognomonic of non-normative decline at the early AD stages.
• Utilize measures that contain a greater number of specific rather than general 
cognitive items. Specific items prompt older adults to search for explicit 
instances in which they experience memory problems in their daily lives, 
which leads to more accurate reporting. Broadly worded items, by contrast, 
may cause older adults to fall back upon global beliefs about their abilities 
and the cognitive aging process more generally [84, 117].
• Ensure that response options correspond to the measurement purpose. When 
the primary purpose is to distinguish between groups, a dichotomous scale 
might be sufficient. For the measurement of change over time, a Likert scale 
might represent a better choice. Notably, to the extent that SCD implies a 
perceived decline, measures should include some items targeting cognitive 
change. Another consideration is whether response options should target the 
frequency of problems (how often) versus quality of performance (how well). 
To address frequency, it is essential to utilize manageable timeframes (e.g., 
number of times the individual misplaced car keys over the past week as 
opposed to the past year). To assess quality of performance, one should keep 
in mind that individuals will provide responses based on aggregated 
experience rather than specific problematic instances [117].
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• Ensure that the reference period is specific, appropriate, and narrow. 
Inquiring about experiences over the past month, week, or even several days 
is preferable to longer timeframes because these windows enable older 
adults to focus on concrete recent events rather than rely on beliefs about 
“typical” performance or the cognitive aging process as a whole [117, 118]. 
Commonly used longer timeframes (e.g., >1 year, 5 years) may seem face 
valid but could pose difficulties for older adults trying to recall specific 
recent events. Vague reference periods should never be used.
C. Consider issues of psychometric adequacy:
• Select questionnaires that have been published, and for which there is at 
least some evidence for adequate reliability, construct validity, test-retest 
reliability, and differences between subgroups of interest.
• Validate measures in the population of interest. For example, some 
instruments might have self and informant versions but have only been 
validated for one or the other population. One cannot assume that validity 
will generalize across populations, particularly as individuals and their 
informants contribute unique sources of variance to estimates of current 
cognitive function.
• Consider whether items appropriately measure the cognitive domains of 
interest. This is especially important in cross-cultural collaborative research, 
where cognitive complaints might not mean the same thing in Western 
versus non-Western settings. Western conceptualizations of executive 
function, for example, often include time pressure/cognitive efficiency, 
which may not generalize. For questionnaires adapted for use in a different 
culture, language, or country, two types of validation must occur: linguistic 
validation (established equivalence of language) and cultural validation 
(item revision based on cultural appropriateness of wording and potential 
misinterpretation due to differences in ways of thinking about cognition) 
[98].
D. Develop new measures:
• There is a need to derive a small number of well-constructed, easy-to-
administer items with adequate reliability across diverse samples of older 
adults. Ideally, these items should discriminate subgroups of SCD, for 
example those with SCD due to preclinical AD from healthy older adults 
(concurrent validity), as well as indicate who of the SCD group is likely to 
decline to MCI and AD (predictive validity). A multi-method approach to 
assessment incorporating objective cognitive and biomarker measures might 
help establish the validity of self-report items.
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Fig. 1. 
Summary of response types and options.
Notes: *14 out of 34 questionnaires include multiple response types. **Includes: <10 each of 
“very poor” to “very well”; “major problems” to “no problems”; “no” to “most of the time”; 
“no” to “definitely”; “no” to “yes, a lot worse”; “no problems” to “always”; and “more 
often” to “about the same”. Includes one each of “no” to “yes, that worries me seriously”; 
“less than 6 months ago” to “more than two years ago”; “very gradually” to “suddenly”; 
“steadily worsened” to “got worse and then leveled off”; “not at all” to “highly”; “excellent” 
to “poor”; “no” to “very much”; agree/disagree; good/poor; same/worse; and suddenly/
gradually”. ***Includes: “always” to “never”; “frequently” to “never”; “always or almost 
always” to “never or almost never”; “very often” to “never”, and “often” to 
“never”. †Includes: “better than ever before” to “worse than ever before”; “much better” to 
“much worse”; “very strong improvement” to “very sharp decline”; “ much improved” to 
“much worse”; “much better now” to “much poorer now”; and “better than when I was 
younger” to “definitely worse than when I was younger”.
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Fig. 2. 
Percentage of items by cognitive domain.
Notes: Memory includes short-term, long-term, episodic, semantic, and prospective memory 
and learning new information; Attention includes basic, sustained, focused, and divided 
attention, working memory, concentration, processing speed, and alertness; Language 
includes expressive and receptive language, word finding, reading, and spelling; Executive 
includes executive functions such as organizing, planning, initiating, switching, multi-
tasking, reasoning, problem solving, decision-making, impulsivity, and self-regulation; 
Calculation includes basic calculation and arithmetic; Orientation includes orientation to 
person, time, place, and situation; General refers to memory and other cognitive abilities 
grouped together in a single item; and Visuospatial includes visuoperception, route finding, 
and directional orientation.
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Table 3
Sample items categorized by ability or change
Domain Referent Sample items
Ability (n = 
374)
Severity Please rate your current level of ability or functioning, or the severity of any problems:
Ability to reason through a complicated problem
1 = above average ability; 2 = normal ability; 3 = mild disability; 4 = mild to moderate disability; 5 = moderate 
disability; 6 = moderate to severe disability; 7 = severe disability; not applicable
How would you rate your memory in terms of the kinds of problems you have?
1, 2 = major problems; 3, 4, 5 = some minor problems; 6,7 = no problems
Frequency How often does remembering or doing the following things present a problem for you?
Losing the thread of thought in conversation
1, 2 = always; 3, 4, 5 = sometimes; 6, 7 = never
I forget details of what I did or what happened the day before.
0 = never or almost never; 1 = rarely; 2 = sometimes; 3 = often; 4 = always or most always
Impact Do you feel that your everyday life is difficult now due to your memory decline?
0 = no; 1 = yes; 2 = prefer not to answer
How is your everyday life affected by the memory problems?
0 = not at all; 1 = a little; 2 = somewhat; 3 = highly
Change (n = 
266)
Temporal Compared to 10 years ago, has there been any change in verbally giving instructions to others?
1 = better or no change; 2 = questionable/occasionally worse; 3 = consistently a little worse; 4 = consistently 
much worse; don’t know
My ability to pay attention to what goes on around me is:
−4 = worse than ever before; −3, −2, −1, 0 = no change; 1, 2, 3, 4 = better than ever before
Atemporal Are you worried or concerned about a decline in your thinking abilities, more than normal aging?
0 = no; 1 = yes
Do you feel your memory got worse suddenly or gradually?
1 = suddenly; 2 = gradually; 3 = other, specify
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Table 4
Sample memory items categorized by item stem specificity
Variable Sample item stems
General memory items (n = 110) How would you rate your memory in terms of the kinds of problems you have?
Do you have problems with your memory compared to the way it was 5 years ago?
Do you feel that you have more problems with memory than most?
Any other problems with your memory?
How long ago did your memory problems start?
Specific memory items (n = 265) How often do you leave something behind when you meant to bring it with you?
Do you have trouble recalling conversations a few days later?
I am good at remembering birthdates.
Compared to your peers, do you think you have more difficulty learning new information?
I forget details about myself (age, telephone number).
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Table 5
Sample cognitive items with double-barreled item stems
Sample item stems
Are you concerned that you have a memory or other thinking problem?
Do you have any difficulty in understanding or following spoken instructions?
Do you talk less because of memory or word-finding difficulties?
Compared to 10 years ago, I am much worse at remembering titles of books, films or plays.
I find it harder to remember street and city names.
Forgets appointments, dates, or where things are stored.
Organizing daily activities and keeping a schedule.
I have trouble finding things in my room, closet, or desk.
Following a story in a book, movie, or TV.
Recalling telephone numbers or zip codes that you use on a daily or weekly basis.
Have you sought evaluation or treatment for your memory problems?
My ability to search through my mind and recall names or memories I know are there is.
Do you find you forget whether you’ve turned off a light or a fire or locked the door?
Remembering what day/date/month it is?
I get lost or I follow the wrong directions on trips, strolls, or buildings that I have previously been in.
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Table 6
Overlap in use of cognitive self-report measures by Subjective Cognitive Decline Initiative (SCD-I) Working 
Group studies
*Questionnaire administered to a subset of participants. Columns with gray shading indicate measures administered in a language other than 
English, as specified below. Columns with line shading indicate measures administered in English plus one or more additional languages, as 
specified below. Working group study numbers: (1) AgeCoDe Study (German); (2) Alzheimer’s Disease Center Clinical Core and Center for Brain 
Health; (3) Alzheimer’s Disease Neuroimaging Initiative (ADNI; English, German, French); (4) Amsterdam Dementia Cohort (Dutch); (5) 
Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL); (6) Barcelona Group (Spanish); (7) Bonn Memory Clinic 
(German); (8) Dartmouth-Indiana Longitudinal Cohort; (9) Einstein Aging Study; (10) Harvard Aging Brain Study; (11) IMAP Caen Group 
(French); (12) Leipzig Longitudinal Study of the Aged (LEILA 75+) (German); (13) Mayo Clinic Study of Aging (MCSA); (14) Memory Clinic -
Fundació ACE (Spanish); (15) PreAl Study (French); (16) Sydney Memory and Ageing Study; (17) University of Pittsburgh Study/ Monongahela-
Youghiogheny Health Aging Team (MYHAT); (18) Vanderbilt Memory and Alzheimer’s Center (VMAC); (19) Victoria Subjective Cognitive 
Decline Study (SCDS).
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Table 7
Ten most frequently occurring cognitive self-report items
Item theme and sample item stems n (%) of total 
items
n (%) of measures 
that contain item
1. Memory change 36 (5.6%) 14 (41.2%)
 How is your memory compared to the way it was 10 years ago?
 Do you feel you remember things less well than you did a year ago?
2. Memory for names of people (longstanding and recently acquired names) 32 (5.0%) 19 (55.9%)
 Do you find you forget people’s names?
 How is your ability to remember the names of close friends and relatives?
3. General memory problems 30 (4.7%) 16 (47.1%)
 Have you noticed difficulty with your memory?
 Do you feel like your memory has become worse?
4. Remembering where you put common objects/finding familiar objects 29 (4.5%) 19 (55.9%)
 Do you feel you are forgetting where things were placed?
 Finding everyday objects? (e.g. keys, wallet)
5. Word finding 19 (3.0%) 15 (44.1%)
 I’m worse at finding the word I want to use in a conversation.
 Do you have more difficulty finding the right words (e.g. feeling like the word is on the tip of 
your tongue)?
6. Remembering appointments 17 (2.7%) 15 (44.1%)
 How is your ability to remember appointments correctly?
 When you actually forget in the following situations, how serious of a problem do you consider 
the memory problem to be?: appointments
7. Remembering recent events 16 (2.5%) 13 (38.2%)
 Do you have more trouble remembering things that have happened recently?
 I forget details of what I did or what happened the day before.
8. Remembering recent conversations/things told to you 15 (2.3%) 14 (41.2%)
 Do you have difficulty remembering a conversation from a few days ago?
 I forget things that I was told yesterday or a few days ago.
9. Memory for intentions 15 (2.3%) 12 (35.3%)
 Beginning to do something and forgetting what you were doing
 Remembering what you entered a room to do
10. Remembering phone numbers (frequently used or just checked) 14 (2.2%) 8 (23.5%)
 Trouble recalling frequently used phone numbers
 Having trouble remembering a telephone number you just looked up
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Table 8
Factors driving questionnaire selection decisions for existing measures (n = 10 SCD-I Working Group studies)
Reason Number (%) of responses
Readily available 8 (19.5%)
Brief/convenient for administration (low participant or researcher burden) 8 (19.5%)
Routinely used in studies of cognitive impairment in aging 7 (17.1%)
Cost-effective (e.g., free/public domain) 5 (12.2%)
Already being used in existing on-site studies 4 (9.8%)
Useful in terms of tapping specific cognitive domains of interest relevant to SCD 4 (9.8%)
Robust in terms of psychometric properties (i.e., reliability and validity) 3 (7.3%)
Good for discriminating differing levels of cognitive impairment 1 (2.4%)
Other considerations 1 (2.4%)
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